Interleukin-35 Attenuates D-Galactosamine/Lipopolysaccharide-Induced Liver Injury via Enhancing Interleukin-10 Production in Kupffer Cells
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Interleukin-35 Attenuates D-Galactosamine/Lipopolysaccharide-Induced Liver Injury via Enhancing Interleukin-10 Production in Kupffer Cells
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2018-08-24
DOI
10.3389/fphar.2018.00959
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Preventive effects of interleukin-6 in lipopolysaccharide/ d -galactosamine induced acute liver injury via regulating inflammatory response in hepatic macrophages
- (2017) Long Li et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- IL-35 recombinant protein reverses inflammatory bowel disease and psoriasis through regulation of inflammatory cytokines and immune cells
- (2017) Yuan Wang et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- IL-12p35 induces expansion of IL-10 and IL-35-expressing regulatory B cells and ameliorates autoimmune disease
- (2017) Ivy M. Dambuza et al. Nature Communications
- β-cell-specific IL-35 therapy suppresses ongoing autoimmune diabetes in NOD mice
- (2016) Fatima Manzoor et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- IL-35 Decelerates the Inflammatory Process by Regulating Inflammatory Cytokine Secretion and M1/M2 Macrophage Ratio in Psoriasis
- (2016) Junfeng Zhang et al. JOURNAL OF IMMUNOLOGY
- IL-35 is elevated in clinical and experimental sepsis and mediates inflammation
- (2015) Ju Cao et al. CLINICAL IMMUNOLOGY
- IL-35 expression in peripheral blood CD4+ T cells from chronic hepatitis B virus-infected patients directly correlates with virus load
- (2015) Yali Zhou et al. CYTOKINE
- IL-35: A potential therapeutic target for controlling hepatitis B virus infection
- (2015) Xiao Gang Xiang et al. Journal of Digestive Diseases
- Interleukin-35 administration counteracts established murine type 1 diabetes – possible involvement of regulatory T cells
- (2015) Kailash Singh et al. Scientific Reports
- Interleukin-35 induces regulatory B cells that suppress autoimmune disease
- (2014) Ren-Xi Wang et al. NATURE MEDICINE
- Kupffer cell-derived IL-10 plays a key role in maintaining humoral immune tolerance in hepatitis B virus-persistent mice
- (2013) Long Xu et al. HEPATOLOGY
- Lipopolysaccharide-Induced M2 to M1 Macrophage Transformation for IL-12p70 Production Is Blocked by Candida albicans Mediated Up-Regulation of EBI3 Expression
- (2013) Xing-Feng Zheng et al. PLoS One
- Th2-Associated Alternative Kupffer Cell Activation Promotes Liver Fibrosis without Inducing Local Inflammation
- (2012) Giuliana López-Navarrete et al. International Journal of Biological Sciences
- Detectable expression of IL-35 in CD4+ T cells from peripheral blood of chronic Hepatitis B patients
- (2011) Fen Liu et al. CLINICAL IMMUNOLOGY
- Protective effects of IL-4 on Bacillus Calmette-Guerin and lipopolysaccharide induced immunological liver injury in mice
- (2011) Nan N. Zhang et al. INFLAMMATION RESEARCH
- Apoptotic cells attenuate fulminant hepatitis by priming Kupffer cells to produce interleukin-10 through membrane-bound TGF-β
- (2010) Minggang Zhang et al. HEPATOLOGY
- The role of intestinal endotoxin in liver injury: A long and evolving history
- (2010) James P. Nolan HEPATOLOGY
- IL-35-mediated induction of a potent regulatory T cell population
- (2010) Lauren W Collison et al. NATURE IMMUNOLOGY
- The β2 integrin CD11b attenuates polyinosinic:Polycytidylic acid-induced hepatitis by negatively regulating natural killer cell functions
- (2009) Minggang Zhang et al. HEPATOLOGY
- Toll-like receptor-induced innate immune responses in non-parenchymal liver cells are cell type-specific
- (2009) Jun Wu et al. IMMUNOLOGY
- Gender influences in vivo human responses to endotoxin
- (2009) Lucas T. van Eijk et al. SHOCK
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started